Kelsey Baxa
Nurse Practitioner · Wilber, NENPI 1063953453
Payments from drug & device makers
Across 74 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$432
- AbbVie$189
- Astellas Pharma US Inc$145
- Organon$115
- Novo Nordisk$79
- Pfizer$63
- plus $361 from 16 others
What the payments were for
- Food & beverage$1,27892%
- Education$1068%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $432 |
| AbbVie | 7 | $189 |
| Astellas Pharma US Inc | 3 | $145 |
| Organon | 5 | $115 |
| Novo Nordisk | 5 | $79 |
| Pfizer | 4 | $63 |
| Lilly USA, LLC | 4 | $59 |
| Mylan Specialty L.p. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Bayer | 2 | $29 |
| Radius Health, Inc. | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Merck | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,384 in reported general payments places this provider in the 75th percentile of 924 nurse practitioner providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $35,329 |
| EliquisApixaban | 29 | $24,587 |
| TrulicityDulaglutide | 14 | $18,165 |
| XareltoRivaroxaban | 15 | $13,423 |
| FarxigaDapagliflozin Propanediol | 21 | $12,805 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $5,951 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $4,369 |
| Gabapentin | 48 | $1,246 |
| Potassium Chloride | 24 | $890 |
| Metoprolol Succinate | 39 | $745 |
| Atorvastatin Calcium | 85 | $696 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $689 |
| Nebivolol Hcl | 13 | $625 |
| Amlodipine Besylate | 67 | $542 |
| Montelukast Sodium | 32 | $425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $79 | $35,32937 claims |
| PfizerEliquis | $63 | $24,58729 claims |
| Lilly USA, LLCTrulicity | $59 | $18,16514 claims |
| Johnson & JohnsonXarelto | $14 | $13,42315 claims |
| MerckJanumet | $17 | $5,95111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Wilber
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Winifred SchaedelPalmyra$64K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Jodi FuehrerGrand Island$25K
- Amanda GuggenmosOmaha$23K
- Lisa OstendorfLincoln$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.